Unknown

Dataset Information

0

Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease.


ABSTRACT: VNI is a potent inhibitor of CYP51 and was recently shown to achieve a parasitological cure of mice infected with T. cruzi in both acute and chronic stages of infection. T. cruzi is the causative parasite of Chagas disease, a neglected tropical disease. The first enantioselective chemical synthesis of VNI (at a materials cost of less than $0.10/mg) is described. Furthermore, the key enantioselective step is performed at the 10 g scale.

SUBMITTER: Dobish MC 

PROVIDER: S-EPMC3528807 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease.

Dobish Mark C MC   Villalta Fernando F   Waterman Michael R MR   Lepesheva Galina I GI   Johnston Jeffrey N JN  

Organic letters 20121207 24


VNI is a potent inhibitor of CYP51 and was recently shown to achieve a parasitological cure of mice infected with T. cruzi in both acute and chronic stages of infection. T. cruzi is the causative parasite of Chagas disease, a neglected tropical disease. The first enantioselective chemical synthesis of VNI (at a materials cost of less than $0.10/mg) is described. Furthermore, the key enantioselective step is performed at the 10 g scale. ...[more]

Similar Datasets

| S-EPMC2727599 | biostudies-literature
| S-EPMC2535926 | biostudies-literature
| S-EPMC2525621 | biostudies-literature
| S-EPMC3698996 | biostudies-literature
| S-EPMC2821456 | biostudies-literature
| S-EPMC3170695 | biostudies-literature
| S-EPMC6991954 | biostudies-literature
| S-EPMC2946328 | biostudies-literature
| S-EPMC3740603 | biostudies-literature
| S-EPMC7760092 | biostudies-literature